Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Quadruple Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests as First-line Treatment for Helicobacter Pylori Infection
NCT05718609Phase 4Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Polymer-based Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 4 trial of rabeprazole, colloidal bismuth pectin, amoxicillin, clarithromycin, furazolidone in Helicobacter pylori infection, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Status: unknown.
02
Drugs
rabeprazolecolloidal bismuth pectinamoxicillinclarithromycinfurazolidone
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT05718609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718609.